Recent articles for private investors with a focus on dividend announcements
Euromoney institutional investor increases 2013 final dividend by 7%
Revenues increased by 3% to £404.7m
Great Portland increases 2014 interim dividend by 3%
Continued growth in both capital and rental values, outperforming London market
ICAP maintains 2014 interim dividend at 6.6p
Group revenue at £736 million was marginally (1%) down on the prior year
London Stock Exchange increases 2013 interim dividend by 4%
Good overall financial performance with headline revenue growth across all of the Group's main business areas
TalkTalk increases 2014 interim dividend by 15.9%
H1 EBITDA £76m in line with expectations, reflecting an additional £86m investment in growth
Land Securities increases 2013 interim dividend by 2.7%
Half-yearly results for the six months ended 30 September 2013
Vodafone increases 2014 interim dividend by 8%
Q2 Group organic service revenue on a management basis1 declined 4.9%; N. & C. Europe down 4.9%; S. Europe down 15.5%; AMAP up 5.7%
Dairy Crest increases 2013 interim dividend by 3.5%
Steady first half performance in challenging trading environment
Astra Zeneca Q3 results
As expected, third quarter revenue declined due to the ongoing impact from products with recent losses of exclusivity. The 4 percent decline in revenue on a constant currency basis, combined with continued investment in our growth platforms and scientific leadership resulted in a greater decline in Core earnings per share. The late-stage pipeline continued to grow; since the half year update there have been three new Phase III programme starts and three regulatory filings were accepted for review.
BT increases 2014 interim dividend by 13%
Gavin Patterson, Chief Executive Officer, commenting on the results, said:
BG Group Q3 Results
CEO, Chris Finlayson, said: "Earnings in the quarter were down 4% to $1.1 billion, largely as a result of lower volumes in both the Upstream and LNG segments. The primary driver for the decline in Upstream volumes is the US, where BG Group has reduced its rig count in line with its strategy of pursuing value over volume. We will see production recover in the fourth quarter with the completion of our North Sea maintenance shutdowns and new projects coming onstream, most notably Jasmine."
Royal Dutch Shell increases 2013 Q3 dividend by 5%
* Royal Dutch Shell's third quarter 2013 earnings, on a current cost of supplies (CCS) basis (see Note 1), were $4.2 billion compared with $6.2 billion in the same quarter a year ago. * Third quarter 2013 CCS earnings excluding identified items (see page 5) were $4.5 billion compared with $6.6 billion in the third quarter of 2012. * Compared with the third quarter 2012, CCS earnings excluding identified items were impacted by significantly weaker industry refining conditions, increased Upstream operating expenses and exploration expenses, as well as production volume impacts from maintenance and asset replacement activities. Earnings also reflected the impact of the challenging operating environment in Nigeria and lower dividends from an LNG venture. This was partly offset by higher contributions from Chemicals and increased underlying Upstream production volumes, led by Integrated Gas. * Basic CCS earnings per share excluding identified items decreased by 32% versus the third quarter 2012. * Cash flow from operating activities for the third quarter 2013 was $10.4 billion, compared with $9.5 billion in the same quarter last year. Excluding working capital movements, cash flow from operating activities for the third quarter 2013 was $9.9 billion, compared with $11.7 billion in the third quarter 2012. * Capital investment for the third quarter 2013 was $9.7 billion. Net capital investment (see Note 1) for the quarter was $9.4 billion. * Total dividends distributed in the quarter were $2.8 billion, of which $1.2 billion were settled under the Scrip Dividend Programme. During the third quarter some 45.5 million shares were bought back for cancellation for a consideration of $1.5 billion. * Gearing at the end of the third quarter 2013 was 11.2%. * A third quarter 2013 dividend has been announced of $0.45 per ordinary share and $0.90 per American Depositary Share ("ADS"), an increase of 5% compared with the third quarter 2012.
BP increases 2013 Q3 dividend 5.5% in dollar terms.
BP's third-quarter replacement cost (RC) profit was $3,178 million, compared with $4,534 million a year ago. After adjusting for a net charge for non-operating items of $522 million and net favourable fair value accounting effects of $8 million (both on a post-tax basis), underlying RC profit for the third quarter was $3,692 million, compared with $5,017 million for the same period in 2012. For the nine months, RC profit was $22,174 million, compared with $9,419 million a year ago. After adjusting for a net gain for non-operating items of $11,536 million and net favourable fair value accounting effects of $19 million (both on a post-tax basis), underlying RC profit for the nine months was $10,619 million, compared with $13,219 million for the same period last year. RC profit or loss for the group, underlying RC profit or loss and fair value accounting effects are non-GAAP measures and further information is provided on pages 3, 19 and 21.
Investors Chronicle dividend of the week - 28/10/2013
This week we are going to continue to be sector based and have a look at the support services sector in the U.K. This is one of the largest sectors and has an interesting array of companies. Our initial selection criterion is the support services sector and this throws up some thirty four companies that are covered by DividendMax.
Glaxo increases 2013 Q3 dividend by 6%
Summary
■
Broadly-based sales growth with Group turnover +1% CER:
-
Pharmaceuticals and Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%, impacted by decline in China sales and Vaccines phasing
-
Consumer Healthcare +4%
-
Total Group turnover ex-divestments +1%
■
Further significant pipeline approvals and filings:
-
4 approvals; US: Tivicay for HIV and FluLaval Q-IV vaccine for flu; Europe: Tafinlar for metastatic melanoma; Japan: Relvar Ellipta for asthma
-
Positive FDA Adcom recommendation for Anoro Ellipta in COPD and positive CHMP opinion for Relvar Ellipta in asthma & COPD
-
3 FDA filings: Arzerra for first-line CLL; dolutegravir-Trii for HIV; fluticasone furoate monotherapy for asthma
■
Continued delivery of operating and financial efficiencies, strong cash generation and returns to shareholders:
-
Net cash inflow from operating activities of £2.1 billion; core tax rate 23.5%
-
Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
-
Q3 dividend: 19p (+6%)
-
£1 billion of shares repurchased by the end of Q3; continue to target £1-2 billion for the year
■
Successful implementation of measures to drive strategic focus and improve growth outlook:
-
Agreement to divest Lucozade and Ribena to Suntory for £1.35 billion and Arixtra/Fraxiparine and related manufacturing site to Aspen for £700 million
■
Full year 2013 guidance reaffirmed:
-
Core EPS growth of 3-4% on sales growth of around 1% (both CER)
5751-5800 of 7440
